 | | Vol. 11.42 – 24 October, 2023 |
| |
|
|
| Scientists reported the results of a first-in-human phase I trial in 41 patients with recurrent glioblastoma who were injected with CAN-3110—an oncolytic herpes virus.
[Nature] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors profiled >300,000 single T cells from healthy children and older adults by using the trimodal assay TEA-seq, which revealed that molecular programming of T cell subsets shifted toward a more activated basal state with age.
[Nature Immunology] |
|
|
|
| Researchers leveraged human-derived microphysiological models to reverse-engineer the HIV-immune system interaction and evaluated the potential of memory-like natural killer cells for HIV+ head and neck cancer.
[Nature Communications] |
|
|
|
| The authors performed single-cell transcriptome analysis of >50,000 airway CD4+ T cells isolated from bronchoalveolar lavage samples from 30 patients with mild and severe asthma.
[Med] |
|
|
|
| The allergenic and inflammatory activity of a designed a recombinant protein, AB-PreS, was tested using basophils and peripheral blood mononuclear cells from birch pollen allergic patients.
[Allergy] |
|
|
|
| Researchers collected metastatic axillary lymph node samples from breast cancer patients who had received standard neoadjuvant therapy. The effect of CD24hiCD27+ Bregs on drug resistance of breast cancer cells was evaluated via in vitro experiments.
[Clinical Cancer Research] |
|
|
|
| Investigators conducted a literature survey and integrated data from multiplexed imaging and methylome-based deconvolution, and also considered cellular mass to determine the distribution of immune cells in terms of both number and total mass.
[Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| Researchers constructed a longitudinal high-precision single-cell transcriptomic landscape of 7,578 CAR-T cells from 26 patients with B cell acute lymphoblastic leukemia post-infusion.
[Cell Reports] |
|
|
|
| Scientists profiled the dynamics and dose dependency of signaling responses in primary human immune cells induced by engineered fusions composed of either wild-type IL-2 or mutant forms with altered affinity, valency, and fusion to the antibody Fc region for stability.
[Science Signaling] |
|  |
|
|
|
| The authors argue for the notion of immunotherapies as “pro-drugs” that act to augment or modulate T cells, which ultimately serve as the drug in vivo, and for the importance of overall immune health in cancer treatment and prevention.
[Immunity] |
|
|
|
|
| SNK01 is an autologous, non-genetically modified natural killer (NK) cell product that has enhanced cytotoxicity and activating receptor expression. This approved trial of 30 patients with moderate Alzheimer’s Disease will look to commence before the end of this year.
[NKGen Biotech Inc.] |
|
|
|
| NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile.
[Nkarta, Inc.] |
|
|
|
|
|
|
|
| | University of Notre Dame – Notre Dame, Indiana, United States |
|
|
|
| | Cancer Research UK Manchester Institute – Manchester, England, United Kingdom |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| | Berlin Institute of Health at Charité – Berlin, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
